MX2010002781A - Combinacion novedosa de angentes terapeuticos. - Google Patents

Combinacion novedosa de angentes terapeuticos.

Info

Publication number
MX2010002781A
MX2010002781A MX2010002781A MX2010002781A MX2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A MX 2010002781 A MX2010002781 A MX 2010002781A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
novel combination
corticosteroid
agonist
nose
Prior art date
Application number
MX2010002781A
Other languages
English (en)
Inventor
Dramane Ibrahim Laine
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010002781A publication Critical patent/MX2010002781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se proporcionan aqu? combinaciones novedosas de un antagonista del receptor de acetilcolina muscar?nica y un agonista beta 2 y/o un corticoesteroide para su administraci?n inhalados por la nariz o por la boca, y m?todos para usarlos.
MX2010002781A 2007-09-12 2008-09-12 Combinacion novedosa de angentes terapeuticos. MX2010002781A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97164607P 2007-09-12 2007-09-12
US9291708P 2008-08-29 2008-08-29
PCT/US2008/076122 WO2009036243A1 (en) 2007-09-12 2008-09-12 Novel combination of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2010002781A true MX2010002781A (es) 2010-04-01

Family

ID=40452490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002781A MX2010002781A (es) 2007-09-12 2008-09-12 Combinacion novedosa de angentes terapeuticos.

Country Status (9)

Country Link
US (1) US20100329996A1 (es)
EP (1) EP2197444A1 (es)
JP (1) JP2010539182A (es)
KR (1) KR20100063116A (es)
CN (1) CN101801378A (es)
BR (1) BRPI0816255A2 (es)
MX (1) MX2010002781A (es)
RU (1) RU2010108640A (es)
WO (1) WO2009036243A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2400950T1 (sl) 2009-02-26 2019-09-30 Glaxo Group Limited Farmacevtske forlmulacije, ki obsegajo 4-((1 R)-2-((6-(2-((2,6- diklorobenzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2- (hidroksimetil)fenol
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
BR112012011787B1 (pt) 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011081937A1 (en) * 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
WO2012049444A1 (en) * 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
MX2013014399A (es) * 2011-06-08 2014-03-21 Glaxo Group Ltd Combinacion que comprende umeclidinio y un corticosteroide.
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
MX2016004316A (es) * 2013-10-07 2016-10-12 Teva Branded Pharmaceutical Products R&D Inc Inhalador de polvo seco.
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
CA2952760A1 (en) 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6696462B2 (en) * 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
AR046103A1 (es) * 2003-10-14 2005-11-23 Glaxo Group Ltd Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion

Also Published As

Publication number Publication date
US20100329996A1 (en) 2010-12-30
WO2009036243A1 (en) 2009-03-19
CN101801378A (zh) 2010-08-11
EP2197444A1 (en) 2010-06-23
KR20100063116A (ko) 2010-06-10
BRPI0816255A2 (pt) 2015-03-17
JP2010539182A (ja) 2010-12-16
RU2010108640A (ru) 2011-10-20

Similar Documents

Publication Publication Date Title
MX2010002781A (es) Combinacion novedosa de angentes terapeuticos.
LUC00077I2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
JO3346B1 (ar) مواد مضادة C5aR
MX2009006304A (es) Nuevos compuestos de oxadiazol.
TW200633715A (en) Medical combinations
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
TW200633706A (en) Medical combinations
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
IN2012DN02735A (es)
IN2012DN02702A (es)
IN2012DN00754A (es)
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
WO2007094876A3 (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2007004976A (es) Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
EP2032127A4 (en) TREATMENT OF PSYCHOLOGICAL PATHOLOGIES USING M1 MUSCARINIC RECEPTOR ANTAGONISTS
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
HK1142823A1 (en) Formulations for the oral administration of therapeutic agents and related methods
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
HK1155943A1 (en) Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
WO2008097536A3 (en) Compositions and methods for treating psychiatric diseases and disorders
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal